Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Sanara MedTech Inc. (SMTI)

    Price:

    32.33 USD

    ( + 2.00 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    SMTI
    Name
    Sanara MedTech Inc.
    Industry
    Medical - Instruments & Supplies
    Sector
    Healthcare
    Price
    32.325
    Market Cap
    287.764M
    Enterprise value
    298.083M
    Currency
    USD
    Ceo
    Ronald T. Nixon
    Full Time Employees
    141
    Ipo Date
    1994-04-07
    City
    Fort Worth
    Address
    1200 Summit Avenue

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Merit Medical Systems, Inc.

    VALUE SCORE:

    8

    Symbol
    MMSI
    Market Cap
    4.897B
    Industry
    Medical - Instruments & Supplies
    Sector
    Healthcare

    2nd position

    DENTSPLY SIRONA Inc.

    VALUE SCORE:

    9

    Symbol
    XRAY
    Market Cap
    2.460B
    Industry
    Medical - Instruments & Supplies
    Sector
    Healthcare

    The best

    Pro-Dex, Inc.

    VALUE SCORE:

    10

    Symbol
    PDEX
    Market Cap
    107.043M
    Industry
    Medical - Instruments & Supplies
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -28.015
    P/S
    2.959
    P/B
    7.865
    Debt/Equity
    1.284
    EV/FCF
    5.368k
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    3.252
    Earnings yield
    -0.036
    Debt/assets
    0.460
    FUNDAMENTALS
    Net debt/ebidta
    20.329
    Interest coverage
    -0.614
    Research And Developement To Revenue
    0.063
    Intangile to total assets
    0.452
    Capex to operating cash flow
    0.984
    Capex to revenue
    0.037
    Capex to depreciation
    0.725
    Return on tangible assets
    -0.183
    Debt to market cap
    0.158
    Piotroski Score
    4.000
    FUNDAMENTALS
    PEG
    -2.107
    P/CF
    77.095
    P/FCF
    4.934k
    RoA %
    -10.062
    RoIC %
    -3.889
    Gross Profit Margin %
    90.613
    Quick Ratio
    2.027
    Current Ratio
    2.263
    Net Profit Margin %
    -10.220
    Net-Net
    -4.140
    FUNDAMENTALS PER SHARE
    FCF per share
    0.007
    Revenue per share
    11.290
    Net income per share
    -1.154
    Operating cash flow per share
    0.424
    Free cash flow per share
    0.007
    Cash per share
    1.969
    Book value per share
    4.109
    Tangible book value per share
    -1.068
    Shareholders equity per share
    4.110
    Interest debt per share
    5.895
    TECHNICAL
    52 weeks high
    39.080
    52 weeks low
    23.530
    Current trading session High
    35.000
    Current trading session Low
    31.480
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -150.697
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -78.773
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    42.038
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -40.208
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.029
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    45.373
    logo

    Country
    BE
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.722
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    11.922
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -11.106
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.747
    DESCRIPTION

    Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

    NEWS
    https://images.financialmodelingprep.com/news/sanara-medtech-to-report-third-quarter-2025-financial-results-20251001.jpeg
    Sanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025

    globenewswire.com

    2025-10-01 07:30:00

    FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its third quarter 2025 financial results on Wednesday, November 12, 2025 before the U.S. financial markets open.

    https://images.financialmodelingprep.com/news/sanara-medtech-growth-remains-strong-as-debt-concerns-recede-20250904.jpg
    Sanara MedTech: Growth Remains Strong As Debt Concerns Recede

    seekingalpha.com

    2025-09-04 14:46:52

    SMTI's Surgical segment revenue grew 28% year-over-year in Q1 to $25.8 million. Surgical segment adjusted EBITDA was $4.7 million, while THP correspondingly posted a loss of $2.1 million. Management is looking at strategic alternatives for THP while planning to cap further investments at $6 million.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-announces-chief-executive-officer-transition-20250902.jpeg
    Sanara MedTech Inc. Announces Chief Executive Officer Transition

    globenewswire.com

    2025-09-02 16:30:00

    Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that Seth Yon, Sanara's President and Chief Commercial Officer, has been appointed to the position of President and Chief Executive Officer and will join the Board of Directors, effective September 15, 2025.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-to-present-at-the-cantor-global-20250827.jpeg
    Sanara MedTech Inc. to Present at the Cantor Global Healthcare Conference on September 3, 2025

    globenewswire.com

    2025-08-27 16:05:00

    FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that management will present at the Cantor Global Healthcare Conference, which is being held at the New York Marriott Marquis in New York, NY from September 2 – 5, 2025. Management will participate in a fireside chat presentation session on Wednesday, September 3 at approximately 2:45 p.m. Eastern Time.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-smti-q2-2025-earnings-call-transcript-20250813.jpg
    Sanara MedTech Inc. (SMTI) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-13 12:18:45

    Sanara MedTech Inc. (NASDAQ:SMTI ) Q2 2025 Earnings Call August 13, 2025 8:00 AM ET Company Participants Elizabeth B. Taylor - Chief Financial Officer Ronald T.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-smti-reports-q2-loss-tops-revenue-20250813.jpg
    Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates

    zacks.com

    2025-08-13 09:26:06

    Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.41 per share a year ago.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-reports-second-quarter2025-financial-results-unaudited-20250813.jpg
    Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

    globenewswire.com

    2025-08-13 07:00:00

    Net Revenue Increased  28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary   ● Net revenue increased 28% to $25.8 million, compared to $20.2 million in the second quarter of 2024.

    https://images.financialmodelingprep.com/news/sanara-medtech-to-report-second-quarter-2025-financial-results-20250715.jpg
    Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

    globenewswire.com

    2025-07-15 16:05:00

    FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-announces-launch-of-tissue-health-plus-20250714.jpg
    Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

    globenewswire.com

    2025-07-14 16:05:00

    Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC (“THP”), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as value-based primary care companies. “We are pleased to announce that, during the second quarter, THP launched a pilot program in partnership with a wound care provider group delivering at-home care for chronic wounds across six states,” said Sam Muppalla, President and CEO of THP.

    https://images.financialmodelingprep.com/news/sanara-medtech-pursuing-rapid-expansion-while-debt-levels-climb-20250609.jpg
    Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb

    seekingalpha.com

    2025-06-09 06:22:50

    Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-smti-q1-2025-earnings-call-transcript-20250514.jpg
    Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript

    seekingalpha.com

    2025-05-14 11:55:29

    Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman, Chief Executive Officer Seth Yon - President, Chief Commercial Officer Sam Muppalla - President, Chief Executive Officer of Tissue Health Plus Elizabeth Taylor - Chief Financial Officer Conference Call Participants Matt Park - Cantor Fitzgerald Operator Welcome to the Sanara MedTech First Quarter of 2025 Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the company's website shortly.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-smti-reports-q1-loss-tops-revenue-20250514.jpg
    Sanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue Estimates

    zacks.com

    2025-05-14 09:51:05

    Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.21 per share a year ago.

    https://images.financialmodelingprep.com/news/sanara-medtech-inc-reports-first-quarter-2025-financial-results-20250514.jpg
    Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

    globenewswire.com

    2025-05-14 07:00:00

    Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary   ● Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024.

    https://images.financialmodelingprep.com/news/sanara-medtech-to-report-first-quarter-2025-financial-results-20250423.jpg
    Sanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025

    globenewswire.com

    2025-04-23 08:00:00

    FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open.

    https://images.financialmodelingprep.com/news/sanara-medtech-to-present-at-the-planet-microcap-showcase-20250410.jpg
    Sanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

    globenewswire.com

    2025-04-10 16:00:00

    FORT WORTH, TX, April 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that management will present at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, which is being held at the Paris Hotel & Casino in Las Vegas, NV from April 22 – 25, 2025. Management will deliver a presentation to investors on Wednesday, April 23 at approximately 3:30 p.m. Pacific Time.

    https://images.financialmodelingprep.com/news/sanara-medtech-smti-stock-jumps-81-will-it-continue-20250410.jpg
    Sanara MedTech (SMTI) Stock Jumps 8.1%: Will It Continue to Soar?

    zacks.com

    2025-04-10 12:40:51

    Sanara MedTech (SMTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.